During the past decade, Xiangyang Central Hospital conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Xiangyang Central Hospital" #1 sponsor was "BeiGene" with 3 trials, followed by "Akeso" with 1 trials sponsored, "Cong-xin Huang" with 1 trials sponsored, "Eli Lilly and Company" with 1 trials sponsored and "Hoffmann-La Roche" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Xiangyang Central Hospital" #1 collaborator was "Chinese Academy of Medical Sciences, Fuwai Hospital" with 1 trials as a collaborator, "Fudan University" with 1 trials as a collaborator, "Nanjing Medical University" with 1 trials as a collaborator, "National Natural Science Foundation of China" with 1 trials as a collaborator and "Shanghai Changzheng Hospital" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Xiangyang Central Hospital" are "Esophageal Squamous Cell Carcinoma (ESCC)" (2 trials), "Acute Coronary Syndrome" (1 trials), "Advanced Non-small Cell Lung Cancer" (1 trials), "Breast Neoplasms" (1 trials) and "Chronic Kidney Diseases" (1 trials). Many other conditions were trialed in "Xiangyang Central Hospital" in a lesser frequency.

Most popular intervention types in "Xiangyang Central Hospital" are "Drug" (11 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (3 trials), "Placebo" (3 trials), "Tislelizumab" (3 trials), "Cisplatin" (2 trials) and "Docetaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Xiangyang Central Hospital" are 12 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Xiangyang Central Hospital". undefined are not yet recruiting, 6 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Xiangyang Central Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Xiangyang Central Hospital, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".